IFNB1 and myeloid sarcoma: Studies of DNA methylation changes have shown that lymphocytes and monocytes from patients with RR-MS present a hypermethylation profile compared to healthy controls, which can be correlated with inflammation and clinical activity of MS since treatment with IFNβ significantly reduce the methylation profile [77].